secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001193125-26-144604
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health FY2025 net loss widens to $53.6M; enters Future Pak deal for non-dilutive capital; Nasdaq appeal pending
--------------------------------------------------------------------------------

- Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
- Net loss attributable to common stockholders FY2025 $53.6M vs $38.5M; loss from operations $45.9M.
- Mytesi prescription volume down 3.7% in 2025 vs 2024; Q4 2025 down 12.2% YoY.
- Entered license agreement with Future Pak Jan 2026: $16M up-front non-dilutive capital, $2M additional upon conditions; FP to commercialize Mytesi and Canalevia-CA1.
- Received Nasdaq noncompliance notice; appeal hearing April 7, 2026; delisting stayed pending decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/0001193125-26-144604-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000119312526144604/d111491d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-144604

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer